Literature DB >> 28884335

Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis.

Aniko Rentka1, Annamaria Nagy1, Jolan Harsfalvi2, Gabriella Szucs3, Zoltan Szekanecz3, Rudolf Gesztelyi4, Peter Szodoray5, Adam Kemeny-Beke6.   

Abstract

The aim of this study was to evaluate the association between clinical signs and symptoms of dry eye disease (DED) in patients with systemic sclerosis (SSc). This cross-sectional observational study included 19 SSc patients and 19 normal subjects with no ocular symptoms or ocular surface disorders. Clinical parameters included tear film break-up time (tBUT), Schirmer I, lissamine green (LG) dye, and tear film osmolarity tests, tear production, and tear secretion flow. For assessment of the dry eye symptoms, the Ocular Surface Disease Index (OSDI) questionnaire was administered to all patients. The following mean values were found in SSc patients: OSDI 33.6 ± 19.86; osmolarity of the tear fluid 310.8 mOsmol/l ± 14.47; tBUT time 5.158 ± 2.328 s; Schirmer I test 5.395 mm/5 min; LG grading score 2.026 ± 0.8893; collected tear fluid volume 6.397 ± 2.761 µl. The calculated average tear velocity was 4.654 ± 1.963 µl/min. A significant correlation was found between the OSDI as a subjective parameter and disease duration. Early recognition of dry eye symptoms, a possible extra-intestinal manifestation of SSc, should be included in the check up of the disease to reduce ocular complications. The objective tear functional tests were strongly influenced by individual factors like age and disease duration.

Entities:  

Keywords:  Lissamine green dye; OSDI; Schirmer I test; Systemic sclerosis; Tear film break-up time; Tear film osmolarity; Tear production; Tear secretion

Mesh:

Year:  2017        PMID: 28884335     DOI: 10.1007/s00296-017-3794-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  [Eye manifestations of generalized scleroderma. (Aspects in common with Sjogren's Syndrome)].

Authors:  C A Stucchi; J D Geiser
Journal:  Doc Ophthalmol       Date:  1967       Impact factor: 2.379

2.  Ocular involvement in a case of scleroderma.

Authors:  R Anand
Journal:  Indian J Ophthalmol       Date:  1985 Jan-Feb       Impact factor: 1.848

3.  Impact of Eyelid Laxity on Symptoms and Signs of Dry Eye Disease.

Authors:  Priyanka Chhadva; Allison L McClellan; Chrisfouad R Alabiad; William J Feuer; Hatim Batawi; Anat Galor
Journal:  Cornea       Date:  2016-04       Impact factor: 2.651

4.  Challenges and pitfalls in clinical trials of treatments for dry eye.

Authors:  Gary N Foulks
Journal:  Ocul Surf       Date:  2003-01       Impact factor: 5.033

Review 5.  Ocular manifestations of scleroderma.

Authors:  Rajen Tailor; Abha Gupta; Ariane Herrick; Jeffrey Kwartz
Journal:  Surv Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 6.048

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 7.  Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

8.  Conjunctival biopsy in scleroderma and primary Sjögren's syndrome.

Authors:  E Mancel; A Janin; D Gosset; P Y Hatron; B Gosselin
Journal:  Am J Ophthalmol       Date:  1993-06-15       Impact factor: 5.258

9.  Prevalence of ocular manifestations in systemic sclerosis patients.

Authors:  Arleta Waszczykowska; Roman Goś; Elżbieta Waszczykowska; Bożena Dziankowska-Bartkowiak; Piotr Jurowski
Journal:  Arch Med Sci       Date:  2013-11-29       Impact factor: 3.318

10.  Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye.

Authors:  Susan Vitale; Linda A Goodman; George F Reed; Janine A Smith
Journal:  Health Qual Life Outcomes       Date:  2004-09-01       Impact factor: 3.186

View more
  7 in total

1.  Predictors for Dry Eye Diseases in Patients with Systemic Sclerosis.

Authors:  Wipada Laovirojjanakul; Yosanan Yospaiboon; Orapin Anutarapongpan; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara; Chingching Foocharoen
Journal:  Clin Ophthalmol       Date:  2022-10-17

2.  Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis.

Authors:  Zoltan Griger; Katalin Danko; Gabor Nemeth; Ziad Hassan; Zsuzsa Aszalos; Katalin Szabo; Levente Bodoki; Rudolf Gesztelyi; Judit Zsuga; Peter Szodoray; Adam Kemeny-Beke
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 3.  Ocular manifestations of rheumatic diseases.

Authors:  Adam Kemeny-Beke; Peter Szodoray
Journal:  Int Ophthalmol       Date:  2019-10-03       Impact factor: 2.031

4.  The Influence of Work Environment Factors on the OcularSurface in a One-Year Follow-Up Prospective Clinical Study.

Authors:  Edyta Chlasta-Twardzik; Aleksandra Górecka-Nitoń; Anna Nowińska; Edward Wylęgała
Journal:  Diagnostics (Basel)       Date:  2021-02-25

Review 5.  Ocular manifestations in patients with systemic sclerosis.

Authors:  Małgorzata Kozikowska; Wojciech Luboń; Eugeniusz J Kucharz; Ewa Mrukwa-Kominek
Journal:  Reumatologia       Date:  2020-12-23

6.  Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity.

Authors:  Caterina Gagliano; Elisa Visalli; Mario Damiano Toro; Roberta Amato; Giovanni Panta; Davide Scollo; Giovanni Scandura; Salvatore Ficili; Giorgio Amato; Alessia Benenati; Roberta Foti; Giulia Malaguarnera; Giuseppe Gagliano; Raffaele Falsaperla; Teresio Avitabile; Rosario Foti
Journal:  Diagnostics (Basel)       Date:  2020-06-13

Review 7.  Dry Eye Disease in Routine Rheumatology Practice.

Authors:  Sevastiani Ziaragkali; Aggeliki Kotsalidou; Nikolaos Trakos
Journal:  Mediterr J Rheumatol       Date:  2018-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.